Francisco Espejo-Porras1,2,3, Laura García-Toscano1,2,3, Carmen Rodríguez-Cueto1,2,3, Irene Santos-García1,2,3, Eva de Lago1,2,3, Javier Fernandez-Ruiz1,2,3. 1. Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. 3. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Abstract
BACKGROUND AND PURPOSE: Cannabinoid CB2 receptors are up-regulated in reactive microglia in the spinal cord of TDP-43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up-regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. EXPERIMENTAL APPROACH: We treated TDP-43 (A315T) transgenic mice with the non-selective agonist WIN55,212-2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU-308, and evaluated their effects on the pathological phenotype. KEY RESULTS: WIN55,212-2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba-1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU-308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl-stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU-308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU-308 reduced the elevated Iba-1 immunostaining in the ventral horn of TDP-43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. CONCLUSIONS AND IMPLICATIONS: Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
BACKGROUND AND PURPOSE:CannabinoidCB2 receptors are up-regulated in reactive microglia in the spinal cord of TDP-43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up-regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. EXPERIMENTAL APPROACH: We treated TDP-43 (A315T) transgenic mice with the non-selective agonist WIN55,212-2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU-308, and evaluated their effects on the pathological phenotype. KEY RESULTS: WIN55,212-2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba-1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU-308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl-stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU-308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU-308 reduced the elevated Iba-1 immunostaining in the ventral horn of TDP-43transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. CONCLUSIONS AND IMPLICATIONS: Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
Authors: Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz Journal: Neuropharmacology Date: 2012-02-08 Impact factor: 5.250
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Iga Wegorzewska; Shaughn Bell; Nigel J Cairns; Timothy M Miller; Robert H Baloh Journal: Proc Natl Acad Sci U S A Date: 2009-10-15 Impact factor: 11.205
Authors: Francisco J Alvarez; Hector Lafuente; M Carmen Rey-Santano; Victoria E Mielgo; Elena Gastiasoro; Miguel Rueda; Roger G Pertwee; Ana I Castillo; Julián Romero; José Martínez-Orgado Journal: Pediatr Res Date: 2008-12 Impact factor: 3.756
Authors: Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Francisco Espejo-Porras; Laura García-Toscano; Carmen Rodríguez-Cueto; Irene Santos-García; Eva de Lago; Javier Fernandez-Ruiz Journal: Br J Pharmacol Date: 2018-05-06 Impact factor: 8.739
Authors: M Galán-Ganga; C Rodríguez-Cueto; J Merchán-Rubira; F Hernández; J Ávila; M Posada-Ayala; J L Lanciego; E Luengo; M G Lopez; A Rábano; J Fernández-Ruiz; I Lastres-Becker Journal: Acta Neuropathol Commun Date: 2021-05-17 Impact factor: 7.801
Authors: Loreto Martínez-González; Carmen Rodríguez-Cueto; Diego Cabezudo; Fernando Bartolomé; Pol Andrés-Benito; Isidro Ferrer; Carmen Gil; Ángeles Martín-Requero; Javier Fernández-Ruiz; Ana Martínez; Eva de Lago Journal: Sci Rep Date: 2020-03-10 Impact factor: 4.379